Dr. Alisa Femia focuses on dermatomyositis, a condition characterized by photosensitivity, severe skin itch, muscle weakness, and internal organ involvement. The speaker outlines traditional and approved therapies, contrasting the benefits and administration burdens of IVIG with newer targeted options. She highlights the recent FDA approval of brepocitinib, a TYK2/JAK1 inhibitor that showed positive results across key clinical endpoints in a 52-week trial. The discussion concludes with a look at investigational agents, including dazukibart, and expresses optimism for future patient care.